Aethlon Medical enrols first patient in trial of Hemopurifier device for cancer [Yahoo! Finance]
Aethlon Medical, Inc. (AEMD)
NASDAQ:AMEX Investor Relations:
ir.aethlonmedical.com
Company Research
Source: Yahoo! Finance
The trial will investigate the device's potential to enhance responses to anti-PD-1 therapies such as Keytruda or Opdivo. Professor Michael Brown and his team enrolled the first participant in the AEMD-2022-06 Hemopurifier Study at the Cancer Clinical Trials Unit at CALHN, Royal Adelaide Hospital. After completing screening on 8 November, the patient will now undergo a two-month run-in period of anti-PD-1 therapy. During this phase, measurements of extracellular vesicles and anti-tumour T-cell activity will take place. Should there be no tumour improvement post-run-in, treatment with the Hemopurifier will ensue, with subsequent monitoring for extracellular vesicle concentration reductions and T-cell activity enhancements. Aethlon Medical's chief medical officer Steven LaRosa said: "Enrolment of the first patient represents the achievement of a critical milestone for Aethlon Medical in the clinical development of the Hemopurifier in oncology. "We are thrilled with the pre-
Show less
Read more
Impact Snapshot
Event Time:
AEMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AEMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AEMD alerts
High impacting Aethlon Medical, Inc. news events
Weekly update
A roundup of the hottest topics
AEMD
News
- Aethlon Medical, Inc. (NASDAQ: AEMD) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Aethlon Medical, Inc. (NASDAQ: AEMD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.MarketBeat
- Biotech and Medical Tech Stocks Report Significant Updates in the Race for Cancer Treatments as Cancer Rates Rise Globally [Yahoo! Finance]Yahoo! Finance
- Aethlon Medical Inc (AEMD) Q2 2025 Earnings Call Highlights: Progress in Oncology Trials and ... [Yahoo! Finance]Yahoo! Finance
- Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
AEMD
Earnings
- 11/13/24 - In-Line
AEMD
Analyst Actions
- 11/15/24 - HC Wainwright
AEMD
Sec Filings
- 11/15/24 - Form S-8
- 11/13/24 - Form 10-Q
- 11/13/24 - Form 8-K
- AEMD's page on the SEC website